Novo drug CagriSema beats Lilly rival in trial
Novo Nordisk announced its experimental drug CagriSema achieved a 12.4 percent average weight loss in a late-stage diabetes trial. The weekly injection outperformed Eli Lillys competing treatment while demonstrating effective blood sugar reduction.
Xurve View
Insights:
Xurve View
NOVO NORDISK A/S-B's experimental drug CagriSema delivered a 12.4% weight loss in a late-stage trial, outperforming rival treatments on Monday morning. The treatment is positioned as a successor to Wegovy, which faces patent expiries after 2030. The trial outcome strengthens the Denmark-based drugmaker's competitive standing in the obesity therapeutics market.
